On June 21, 2024, Sun Pharmaceutical Industries Limited (Sun Pharma and its subsidiaries and associate companies) signed a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited. This agreement allows Sun Pharma to market Vonoprazan tablets, available in 10 and 20 mg doses, in India under the brand name “Voltapraz”. Vonoprazan is a new, orally …


